CTLA-4 blockade increases IFN-producing CD 4 ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients


Significant anti-tumor responses have been reported in a small subset of cancer patients treated with the immunotherapeutic agent antiCTLA-4 antibody. All clinical trials to date, comprising over 3,000 patients, have been conducted in the metastatic disease setting, which allows for correlation of drug administration with clinical outcome but has limited… (More)

5 Figures and Tables


  • Presentations referencing similar topics